Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda
Authors:
Open Access
- 7 March 2007
- journal article
- Published by Wiley in HIV Medicine
- Vol. 8 (2) , 86-91
Abstract
Objectives: Polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been shown to influence nevirapine plasma concentrations in HIV‐infected European Caucasians. Although nevirapine is used extensively in Africa, the influence of CYP2B6 genotype on nevirapine exposure has not been assessed in this population. We aimed to determine the influence of CYP2B6 genotype at position 516 on nevirapine trough concentrations in HIV‐infected patients in Kampala, Uganda. Additional polymorphisms in the CYP and multidrug resistance protein‐1 (MDR‐1) genes were also assessed for their impact on nevirapine concentrations.Methods: The following genotypes were determined in all subjects using polymerase chain reaction–restriction fragment length polymorphism: CYP2B6 G516T, MDR‐1 C3435T and G2677T, CYP3A4*1B and CYP3A5*3. Nevirapine plasma concentrations were determined using high‐performance liquid chromatography in 23 HIV‐infected patients who were generally healthy and had been taking nevirapine 200 mg twice daily for at least 14 days. Analysis of variance with post hoc testing was used to compare nevirapine concentrations among CYP2B6 genotype groups.Results: The median nevirapine trough concentration in individuals homozygous for the variant allele (TT) was 7607 ng/mL vs 4181 and 5559 ng/mL for GG and GT individuals, respectively (GG vs TT median ratio=1.82;P=0.011). The mean ratio for TT vs GG individuals (95% confidence interval) was 1.51 (1.18, 1.84). No associations were observed between the other polymorphisms studied and nevirapine concentrations.Conclusions: CYP2B6 G516T significantly influenced nevirapine trough concentrations in HIV‐infected patients in Uganda. Additional studies in larger patient populations are necessary to further define the potential clinical impact of these preliminary findings.Keywords
This publication has 24 references indexed in Scilit:
- Nevirapine Plasma Concentrations are Still Detectable After More Than 2 Weeks in the Majority of Women Receiving Single-Dose NevirapineJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Single‐Dose Nevirapine and Drug Resistance: The More You Look, the More You FindThe Journal of Infectious Diseases, 2005
- Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected SubjectsClinical Infectious Diseases, 2005
- Efavirenz Intoxication Due to Slow Hepatic MetabolismClinical Infectious Diseases, 2005
- Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochemical and Biophysical Research Communications, 2004
- Comparison of Nevirapine (NVP) Resistance in Ugandan Women 7 Days vs. 6–8 Weeks after Single-Dose NVP Prophylaxis: HIVNET 012AIDS Research and Human Retroviruses, 2004
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Role of polymorphic human CYP2B6 in cyclophosphamide bioactivationThe Pharmacogenomics Journal, 2003
- A Single Nucleotide Polymorphism of CYP2B6 Found in Japanese Enhances Catalytic Activity by AutoactivationBiochemical and Biophysical Research Communications, 2001
- Pharmacokinetics of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their NeonatesThe Journal of Infectious Diseases, 1998